Present situation of CMO raw material drug outsourcing
Custom Synthesis ,At present, the development of the international medicine situation has promoted the rapid growth of CMO in China, and has a strong competitive advantage in the production value, growth rate and enterprise level, but there are some problems to be improved. This paper analyzes the current situation of the outsourcing of CMO in China, and points out that we should continue to strengthen communication with the international market, improve the production technology and management level, and enhance the environmental protection consciousness, in order to better integrate with the international and promote the new development of the CMO raw material drug outsourcing industry.
Some of the first-step CMO API companies began to look to those multinational companies patented products or patents will expire products, there is a destination to negotiate with the production, and even specifically to set up a joint venture, more typical products include statins, south-class antibiotics.
In addition, the World Health Organization, as well as aid organizations in the major regions, take the form of government procurement for the treatment of diseases that are important, problematic and influential in human relations, such as antimalarial drugs, anti-AIDS drugs, and anti-tuberculosis drugs. When the multinational companies received the order, in consideration of the cost of the case, the order of the drugs to the production of developing country pharmaceutical companies, in China is more typical of artemisinin, zidovudine, aspergillus, etc.http://www.haihengpharma.com/present-situation-of-cmo-raw-material-drug-outsourcing/News